TY  - JOUR
TI  - The effect of tocilizumab on severe COVID-19
infection: Review of current evidence
AB  - The COVID-19 outbreak that spread in December 2019 has caused the death
of millions of people in a short time. Many studies published recently have
shown that many cytokines (interleukin (IL) IL-1, IL-2, IL-6, TNF and IFN-) are
significantly increased in COVID-19 patients with pneumonia, and especially
IL-6 in combination with other cytokines has shown to be the main cause of
the cytokine storm. Since IL-6 level is associated with clinical worsening in
COVID-19 patients, anti-IL-6 therapy is seen as a promising treatment.
Tocilizumab, a widely used IL-6 antagonist, was approved by the FDA in 2017
for Cytokine Storm Syndrome (CSS). Its addition to the treatment in COVID19 patients with increased blood IL-6 levels and oxygen saturation <92% has
been recommended due to bilateral widespread pulmonary infiltration. We
summarized the studies on tocilizumab and COVID-19 disease published in
the literature. In the light of current information, data on the mechanism of the
action of tocilizumab, which is still widely used in COVID-19 patients, appropriate patient selection, effectiveness in treatment and side effects are presented.
AU  - Inonu Koseoglu, Handan
AU  - Pazarlı, Ahmet Cemal
AU  - Kanbay, Asiye
AU  - Yakar, Halil Ibrahim
DO  - 10.5578/tt.20219909
PY  - 2021
JO  - Tüberküloz ve Toraks
VL  - 69
IS  - 1
SN  - 0494-1373
SP  - 74
EP  - 83
DB  - TRDizin
UR  - http://search/yayin/detay/509055
ER  -